The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Aditya Birla Capital Shares Jump 4% on Gold Loan Foray
• Crompton Greaves Shares Rise on FY29-31 Outlook
• Escorts Kubota to Invest Rs 2,000 Crore in New UP Plant
• Brigade Enterprises Shares Jump 6% on HealthEdge Lease Deal
• Dhoot Transmission Hits 52-Week High, Stock Up 70% From IPO

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.